Histaminergic system in brain disorders: Lessons from the translational approach and future perspectives

Annals of General Psychiatry

Volumn 13, Issue 1, 2014, Pages

  Baronio, Diego ^a,b   Gonchoroski, Taylor ^a,b   Castro, Kamila ^a,b   Zanatta, Geancarlo ^a,b   Gottfried, Carmem ^a,b   Riesgo, Rudimar ^a,b,c  

^a Translational Research Group in Autism Spectrum Disorders (GETTEA)   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Antagonist; Autism; Brain disorders; Histamine; Histaminergic system

Indexed keywords

1 (5 CHLORO 2 INDOLYLCARBONYL) 4 METHYLPIPERAZINE; 6 (3 CYCLOBUTYL 2,3,4,5 TETRAHYDRO 1H 3 BENZAZEPIN 7 YLOXY) N METHYLNICOTINAMIDE; ABT 288; ANTIHISTAMINIC AGENT; BAVISANT; BETAHISTINE; CHLORPHENIRAMINE; CIPROXIFAN; DIMEBON; DOXEPIN; FAMOTIDINE; HISTAMINE; HISTAMINE H1 RECEPTOR; HISTAMINE H2 RECEPTOR; HISTAMINE H3 RECEPTOR; HISTAMINE H4 RECEPTOR; OLANZAPINE; PITOLISANT; REBOXETINE; THIOPERAMIDE; TOREFORANT;

ADDICTION; ALZHEIMER DISEASE; AUTISM; BRAIN DISEASE; HUMAN; NEUROTRANSMISSION; NOCICEPTION; NONHUMAN; PAIN; PARKINSON DISEASE; REVIEW; SCHIZOPHRENIA; SLEEP DISORDER;

EID: 84924257524     PISSN: None     EISSN: 1744859X     Source Type: Journal    
DOI: 10.1186/s12991-014-0034-y     Document Type: Review

References (115)

1. Dale HH, Laidlaw PP: The physiological action of beta-iminazolylethylamine. J Physiol 1910, 41(5):318-344.
2. Haas HL, Sergeeva OA, Selbach O: Histamine in the nervous system. Physiol Rev 2008, 88(3):1183-1241.
3. Schwartz JC, Arrang JM, Garbarg M, Pollard H, Ruat M: Histaminergic transmission in the mammalian brain. Physiol Rev 1991, 71(1):1-51.
4. Gulat-Marnay C, Lafitte A, Arrang JM, Schwartz JC: Regulation of histamine release and synthesis in the brain by muscarinic receptors. J Neurochem 1989, 52(1):248-254.
5. Gulat-Marnay C, Lafitte A, Arrang JM, Schwartz JC: Modulation of histamine release in the rat brain by kappa-opioid receptors. J Neurochem 1990, 55(1):47-53.
6. Arrang JM, Gulat-Marnay C, Defontaine N, Schwartz JC: Regulation of histamine release in rat hypothalamus and hippocampus by presynaptic galanin receptors. Peptides 1991, 12(5):1113-1117.
7. Panula P, Airaksinen MS, Pirvola U, Kotilainen E: A histamine-containing neuronal system in human brain. Neuroscience 1990, 34(1):127-132.
8. Sundvik M, Kudo H, Toivonen P, Rozov S, Chen YC, Panula P: The histaminergic system regulates wakefulness and orexin/hypocretin neuron development via histamine receptor H1 in zebrafish. FASEB J 2011, 25(12):4338-4347.
9. Ishizuka T, Yamatodani A: Integrative role of the histaminergic system in feeding and taste perception. Front Syst Neurosci 2012, 6:44.
10. Benetti F, da Silveira CK, da Silva WC, Cammarota M, Izquierdo I: Histamine reverses a memory deficit induced in rats by early postnatal maternal deprivation. Neurobiol Learn Mem 2012, 97(1):54-58.
11. Ash AS, Schild HO: Receptors mediating some actions of histamine. Br J Pharmacol Chemother 1966, 27(2):427-439.
12. Nijmeijer S, Leurs R, Vischer HF: Constitutive activity of the histamine H(1) receptor. Methods Enzymol 2010, 484:127-147.
13. Threlfell S, Exley R, Cragg SJ, Greenfield SA: Constitutive histamine H2 receptor activity regulates serotonin release in the substantia nigra. J Neurochem 2008, 107(3):745-755.
14. Bhowmik M, Khanam R, Vohora D: Histamine H3 receptor antagonists in relation to epilepsy and neurodegeneration: a systemic consideration of recent progress and perspectives. Br J Pharmacol 2012, 167(7):1398-1414.
15. Schneider EH, Schnell D, Strasser A, Dove S, Seifert R: Impact of the DRY motif and the missing "ionic lock" on constitutive activity and G-protein coupling of the human histamine H4 receptor. J Pharmacol Exp Ther 2010, 333(2):382-392.
16. Seifert R, Wenzel-Seifert K: Constitutive activity of G-protein-coupled receptors: cause of disease and common property of wild-type receptors. Naunyn Schmiedebergs Arch Pharmacol 2002, 366(5):381-416.
17. Tao YX: Constitutive activation of G protein-coupled receptors and diseases: insights into mechanisms of activation and therapeutics. Pharmacol Ther 2008, 120(2):129-148.
18. Bond RA, Ijzerman AP: Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends Pharmacol Sci 2006, 27(2):92-96.
19. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov 2006, 5(12):993-996.
20. Hill SJ, Young JM: Evidence for the presence of histamine H1-receptors in guinea-pig brain [proceedings]. Br J Pharmacol 1978, 63(2):394P.
21. Chang RS, Tran VT, Snyder SH: Characteristics of histamine H1-receptors in peripheral tissues labeled with [3H]mepyramine. J Pharmacol Exp Ther 1979, 209(3):437-442.
22. Shimamura T, Shiroishi M, Weyand S, Tsujimoto H, Winter G, Katritch V, Abagyan R, Cherezov V, Liu W, Han GW, Kobayashi T, Stevens RC, Iwata S: Structure of the human histamine H1 receptor complex with doxepin. Nature 2011, 475(7354):65-70.
23. Smit MJ, Hoffmann M, Timmerman H, Leurs R: Molecular properties and signalling pathways of the histamine H1 receptor. Clin Exp Allergy 1999, 29(Suppl 3):19-28.
24. Masuoka T, Kamei C: Role of hippocampal H1 receptors in radial maze performance and hippocampal theta activity in rats. Brain Res Bull 2007, 73(4-6):231-237.
25. Huang ZL, Mochizuki T, Qu WM, Hong ZY, Watanabe T, Urade Y, Hayaishi O: Altered sleep-wake characteristics and lack of arousal response to H3 receptor antagonist in histamine H1 receptor knockout mice. Proc Natl Acad Sci U S A 2006, 103(12):4687-4692.
26. Lundius EG, Sanchez-Alavez M, Ghochani Y, Klaus J, Tabarean IV: Histamine influences body temperature by acting at H1 and H3 receptors on distinct populations of preoptic neurons. J Neurosci 2010, 30(12):4369-4381.
27. Mobarakeh JI, Sakurada S, Katsuyama S, Kutsuwa M, Kuramasu A, Lin ZY, Watanabe T, Hashimoto Y, Yanai K: Role of histamine H(1) receptor in pain perception: a study of the receptor gene knockout mice. Eur J Pharmacol 2000, 391(1-2):81-89.
28. Black JW, Duncan WA, Durant CJ, Ganellin CR, Parsons EM: Definition and antagonism of histamine H 2 -receptors. Nature 1972, 236(5347):385-390.
29. Hegstrand LR, Kanof PD, Greengard P: Histamine-sensitive adenylate cyclase in mammalian brain. Nature 1976, 260(5547):163-165.
30. Dai H, Kaneko K, Kato H, Fujii S, Jing Y, Xu A, Sakurai E, Kato M, Okamura N, Kuramasu A, Yanai K: Selective cognitive dysfunction in mice lacking histamine H1 and H2 receptors. Neurosci Res 2007, 57(2):306-313.
31. 2 histamine receptor dependent modulation of body temperature and neuronal activity in the medial preoptic nucleus. Neuropharmacology 2012, 63(2):171-180.
32. Alonso N, Fernandez N, Notcovich C, Monczor F, Simaan M, Baldi A, Gutkind JS, Davio C, Shayo C: Cross-desensitization and cointernalization of H1 and H2 histamine receptors reveal new insights into histamine signal integration. Mol Pharmacol 2013, 83(5):1087-1098.
33. Saligrama N, Noubade R, Case LK, del Rio R, Teuscher C: Combinatorial roles for histamine H1-H2 and H3-H4 receptors in autoimmune inflammatory disease of the central nervous system. Eur J Immunol 2012, 42(6):1536-1546.
34. Cangioli I, Baldi E, Mannaioni PF, Bucherelli C, Blandina P, Passani MB: Activation of histaminergic H3 receptors in the rat basolateral amygdala improves expression of fear memory and enhances acetylcholine release. Eur J Neurosci 2002, 16(3):521-528.
35. Gemkow MJ, Davenport AJ, Harich S, Ellenbroek BA, Cesura A, Hallett D: The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today 2009, 14(9-10):509-515.
36. Bakker RA, Timmerman H, Leurs R: Histamine receptors: specific ligands, receptor biochemistry, and signal transduction. Clin Allergy Immunol 2002, 17:27-64.
37. Bongers G, Sallmen T, Passani MB, Mariottini C, Wendelin D, Lozada A, Marle A, Navis M, Blandina P, Bakker RA, Panula P, Leurs R: The Akt/GSK-3beta axis as a new signaling pathway of the histamine H(3) receptor. J Neurochem 2007, 103(1):248-258.
38. Mariottini C, Scartabelli T, Bongers G, Arrigucci S, Nosi D, Leurs R, Chiarugi A, Blandina P, Pellegrini-Giampietro DE, Passani MB: Activation of the histaminergic H3 receptor induces phosphorylation of the Akt/GSK-3 beta pathway in cultured cortical neurons and protects against neurotoxic insults. J Neurochem 2009, 110(5):1469-1478.
39. Gomez-Ramirez J, Ortiz J, Blanco I: Presynaptic H3 autoreceptors modulate histamine synthesis through cAMP pathway. Mol Pharmacol 2002, 61(1):239-245.
40. Yamasaki T, Tamai I, Matsumura Y: Activation of histamine H3 receptors inhibits renal noradrenergic neurotransmission in anesthetized dogs. Am J Physiol Regul Integr Comp Physiol 2001, 280(5):R1450-R1456.
41. Gondard E, Anaclet C, Akaoka H, Guo RX, Zhang M, Buda C, Franco P, Kotani H, Lin JS: Enhanced histaminergic neurotransmission and sleep-wake alterations, a study in histamine H3-receptor knock-out mice. Neuropsychopharmacology 2013, 38(6):1015-1031.
42. Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K: Molecular cloning and characterization of a new human histamine receptor, HH4R. Biochem Biophys Res Commun 2000, 279(2):615-620.
43. Zampeli E, Tiligada E: The role of histamine H4 receptor in immune and inflammatory disorders. Br J Pharmacol 2009, 157(1):24-33.
44. Moya-Garcia AA, Rodriguez CE, Morilla I, Sanchez-Jimenez F, Ranea JA: The function of histamine receptor H4R in the brain revealed by interaction partners. Front Biosci (Schol Ed) 2011, 3:1058-1066.
45. Simon T, Laszlo V, Lang O, Buzas E, Falus A: Histamine regulates relevant murine dendritic cell functions via H4 receptor. Front Biosci (Elite Ed) 2011, 3:1414-1424.
46. Mommert S, Gschwandtner M, Koether B, Gutzmer R, Werfel T: Human memory Th17 cells express a functional histamine H4 receptor. Am J Pathol 2012, 180(1):177-185.
47. Karlstedt K, Jin C, Panula P: Expression of histamine receptor Hrh3 and Hrh4 in rat brain endothelial cells. Br J Pharmacol 2013, 170(1):58-66.
48. Strakhova MI, Nikkel AL, Manelli AM, Hsieh GC, Esbenshade TA, Brioni JD, Bitner RS: Localization of histamine H4 receptors in the central nervous system of human and rat. Brain Res 2009, 1250:41-48.
49. Naddafi F, Mirshafiey A: The neglected role of histamine in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2013, 28(4):327-336.
50. Brown JW, Whitehead CA, Basso AM, Rueter LE, Zhang M: Preclinical evaluation of non-imidazole histamine H(3) receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. Int J Neuropsychopharmacol 2013, 16(4):889-904.
51. Iwabuchi K, Ito C, Tashiro M, Kato M, Kano M, Itoh M, Iwata R, Matsuoka H, Sato M, Yanai K: Histamine H1 receptors in schizophrenic patients measured by positron emission tomography. Eur Neuropsychopharmacol 2005, 15(2):185-191.
52. Nishino S, Sakurai E, Nevsimalova S, Yoshida Y, Watanabe T, Yanai K, Mignot E: Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls. Sleep 2009, 32(2):175-180.
53. Rojas-Zamorano JA, Esqueda-Leon E, Jimenez-Anguiano A, Cintra-McGlone L, Mendoza Melendez MA, Velazquez Moctezuma J: The H1 histamine receptor blocker, chlorpheniramine, completely prevents the increase in REM sleep induced by immobilization stress in rats. Pharmacol Biochem Behav 2009, 91(3):291-294.
54. Bezprozvanny I: The rise and fall of Dimebon. Drug News Perspect 2010, 23(8):518-523.
55. Lankford A, Rogowski R, Essink B, Ludington E, Heith Durrence H, Roth T: Efficacy and safety of doxepin 6 mg in a four-week outpatient trial of elderly adults with chronic primary insomnia. Sleep Med 2012, 13(2):133-138.
56. Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, Postuma RB: Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson's disease-a randomized study. Parkinsonism Relat Disord 2013, 19(7):670-675.
57. Linday LA, Tsiouris JA, Cohen IL, Shindledecker R, DeCresce R: Famotidine treatment of children with autistic spectrum disorders: pilot research using single subject research design. J Neural Transm 2001, 108(5):593-611.
58. Deutsch SI, Rosse RB, Kendrick KA, Fay-McCarthy M, Collins JP, Wyatt RJ: Famotidine adjunctive pharmacotherapy for schizophrenia: preliminary data. Clin Neuropharmacol 1993, 16(6):518-524.
59. Meskanen K, Ekelund H, Laitinen J, Neuvonen PJ, Haukka J, Panula P, Ekelund J: A randomized clinical trial of histamine 2 receptor antagonism in treatment-resistant Schizophrenia. J Clin Psychopharmacol 2013, 33(4):472-478.
60. 3 receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. Curr Alzheimer Res 2013, 10(3):240-251.
61. Haig GM, Pritchett Y, Meier A, Othman AA, Hall C, Gault LM, Lenz RA: A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. J Alzheimers Dis 2014, 42(3):959-971.
62. Haig GM, Bain E, Robieson W, Othman AA, Baker J, Lenz RA: A randomized trial of the efficacy and safety of the H3 antagonist ABT-288 in cognitive impairment associated with Schizophrenia. Schizophr Bull 2014, 40(6):1433-1442.
63. Galici R, Boggs JD, Aluisio L, Fraser IC, Bonaventure P, Lord B, Lovenberg TW: JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology 2009, 56(8):1131-1137.
64. Lin JS, Dauvilliers Y, Arnulf I, Bastuji H, Anaclet C, Parmentier R, Kocher L, Yanagisawa M, Lehert P, Ligneau X, Perrin D, Robert P, Roux M, Lecomte JM, Schwartz JC: An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients. Neurobiol Dis 2008, 30(1):74-83.
65. Weisler RH, Pandina GJ, Daly EJ, Cooper K, Gassmann-Mayer C, Investigators AS: Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder. CNS Drugs 2012, 26(5):421-434.
66. Poyurovsky M, Fuchs C, Pashinian A, Levi A, Weizman R, Weizman A: Reducing antipsychotic-induced weight gain in schizophrenia: a double-blind placebo-controlled study of reboxetine-betahistine combination. Psychopharmacology (Berl) 2013, 226(3):615-622.
67. Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, Boggs J, Welty N, Shoblock JR, Motley ST, Letavic MA, Carruthers NI, Dugovic C, Lovenberg TW, Bonaventure P: JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl) 2011, 214(4):829-841.
68. Browman KE, Komater VA, Curzon P, Rueter LE, Hancock AA, Decker MW, Fox GB: Enhancement of prepulse inhibition of startle in mice by the H3 receptor antagonists thioperamide and ciproxifan. Behav Brain Res 2004, 153(1):69-76.
69. Nowak P, Noras L, Jochem J, Szkilnik R, Brus H, Körossy E, Drab J, Kostrzewa RM, Brus R: Histaminergic activity in a rodent model of Parkinson's disease. Neurotox Res 2009, 15(3):246-251.
70. Medhurst SJ, Collins SD, Billinton A, Bingham S, Dalziel RG, Brass A, Roberts JC, Medhurst AD, Chessell IP: Novel histamine H3 receptor antagonists GSK189254 and GSK334429 are efficacious in surgically-induced and virally-induced rat models of neuropathic pain. Pain 2008, 138(1):61-69.
71. Hsieh GC, Honore P, Pai M, Wensink EJ, Chandran P, Salyers AK, Wetter JM, Zhao C, Liu H, Decker MW, Esbenshade TA, Cowart MD, Brioni JD: Antinociceptive effects of histamine H3 receptor antagonist in the preclinical models of pain in rats and the involvement of central noradrenergic systems. Brain Res 2010, 1354:74-84.
72. 3 -receptor antagonist, displays procognitive effects in rodents. Pharmacol Biochem Behav 2012, 102(2):203-214.
73. Bardgett ME, Davis NN, Schultheis PJ, Griffith MS: Ciproxifan, an H3 receptor antagonist, alleviates hyperactivity and cognitive deficits in the APP Tg2576 mouse model of Alzheimer's disease. Neurobiol Learn Mem 2011, 95(1):64-72.
74. 4 receptor antagonist JNJ7777120 in a murine model of acute skin inflammation. Exp Dermatol 2012, 21(1):32-37.
75. Hsieh GC, Chandran P, Salyers AK, Pai M, Zhu CZ, Wensink EJ, Witte DG, Miller TR, Mikusa JP, Baker SJ, Wetter JM, Marsh KC, Hancock AA, Cowart MD, Esbenshade TA, Brioni JD, Honore P: H4 receptor antagonism exhibits anti-nociceptive effects in inflammatory and neuropathic pain models in rats. Pharmacol Biochem Behav 2010, 95(1):41-50.
76. Liu WL: Histamine H4 receptor antagonists for the treatment of inflammatory disorders. Drug Discov Today 2014, 19(8):1222-1225.
77. Thies W, Bleiler L: Association As: 2013 Alzheimer's disease facts and figures. Alzheimers Dement 2013, 9(2):208-245.
78. Shan L, Bossers K, Unmehopa U, Bao AM, Swaab DF: Alterations in the histaminergic system in Alzheimer's disease: a postmortem study. Neurobiol Aging 2012, 33(11):2585-2598.
79. Kim SH, Cairns N, Fountoulakisc M, Lubec G: Decreased brain histamine-releasing factor protein in patients with Down syndrome and Alzheimer's disease. Neurosci Lett 2001, 300(1):41-44.
80. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D, investigators d: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 2008, 372(9634):207-215.
81. Grove RA, Harrington CM, Mahler A, Beresford I, Maruff P, Lowy MT, Nicholls AP, Boardley RL, Berges AC, Nathan PJ, Horrigan JP: A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Curr Alzheimer Res 2014, 11(1):47-58.
82. Vanni-Mercier G, Sakai K, Jouvet M: [Specific neurons for wakefulness in the posterior hypothalamus in the cat]. C R Acad Sci III 1984, 298(7):195-200.
83. Parmentier R, Ohtsu H, Djebbara-Hannas Z, Valatx JL, Watanabe T, Lin JS: Anatomical, physiological, and pharmacological characteristics of histidine decarboxylase knock-out mice: evidence for the role of brain histamine in behavioral and sleep-wake control. J Neurosci 2002, 22(17):7695-7711.
84. Kanbayashi T, Kodama T, Kondo H, Satoh S, Inoue Y, Chiba S, Shimizu T, Nishino S: CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome. Sleep 2009, 32(2):181-187.
85. 1 histamine receptor antagonists produce different sleep-inducing profiles in rats. Eur J Pharmacol 2012, 683(1-3):179-185.
86. Inocente C, Arnulf I, Bastuji H, Thibault-Stoll A, Raoux A, Reimão R, Lin JS, Franco P: Pitolisant, an inverse agonist of the histamine H3 receptor: an alternative stimulant for narcolepsy-cataplexy in teenagers with refractory sleepiness. Clin Neuropharmacol 2012, 35(2):55-60.
87. Jucaite A, Takano A, Boström E, Jostell KG, Stenkrona P, Halldin C, Segerdahl M, Nyberg S: AZD5213: a novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. Int J Neuropsychopharmacol 2013, 16(6):1231-1239.
88. Jouan L, Girard SL, Dobrzeniecka S, Ambalavanan A, Krebs MO, Joober R, Gauthier J, Dion PA, Rouleau GA: Investigation of rare variants in LRP1, KPNA1, ALS2CL and ZNF480 genes in schizophrenia patients reflects genetic heterogeneity of the disease. Behav Brain Funct 2013, 9:9.
89. Seeman P: Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 2010, 4(1):56-73.
90. Bishara D: Once-monthly paliperidone injection for the treatment of schizophrenia. Neuropsychiatr Dis Treat 2010, 6:561-572.
91. Jin CY, Anichtchik O, Panula P: Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases. Br J Pharmacol 2009, 157(1):118-129.
92. Wei Z, Wang L, Yu T, Wang Y, Sun L, Wang T, Huo R, Li Y, Wu X, Qin S, Xu Y, Feng G, He L, Xing Q: Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy. J Clin Psychopharmacol 2013, 33(2):221-225.
93. Rosse RB, Kendrick K, Fay-McCarthy M, Prell GD, Rosenberg P, Tsui LC, Wyatt RJ, Deutsch SI: An open-label study of the therapeutic efficacy of high-dose famotidine adjuvant pharmacotherapy in schizophrenia: preliminary evidence for treatment efficacy. Clin Neuropharmacol 1996, 19(4):341-348.
94. 3 receptor-ligands in experimental models of schizophrenia. Arzneimittelforschung 2012, 62(5):222-229.
95. Wong MM, Chen EY, Lui SS, Tso S: Medication adherence and subjective weight perception in patients with first-episode psychotic disorder. Clin Schizophr Relat Psychoses 2011, 5(3):135-141.
96. Xia Y, Ma D, Hu J, Tang C, Wu Z, Liu L, Xin F: Effect of metabotropic glutamate receptor 3 genotype on N-acetylaspartate levels and neurocognition in non-smoking, active alcoholics. Behav Brain Funct 2012, 8:42.
97. Wang TY, Lee SY, Chen SL, Chang YH, Chen SH, Chu CH, Huang SY, Tzeng NS, Wang CL, Lee IH, Yeh TL, Yang YK, Lu RB: Interaction between serotonin transporter and serotonin receptor 1 B genes polymorphisms may be associated with antisocial alcoholism. Behav Brain Funct 2012, 8:18.
98. Guindalini C, Laranjeira R, Collier D, Messas G, Vallada H, Breen G: Dopamine-beta hydroxylase polymorphism and cocaine addiction. Behav Brain Funct 2008, 4:1.
99. Oroszi G, Enoch MA, Chun J, Virkkunen M, Goldman D: Thr105Ile, a functional polymorphism of histamine N-methyltransferase, is associated with alcoholism in two independent populations. Alcohol Clin Exp Res 2005, 29(3):303-309.
100. Nuutinen S, Panula P: Histamine in neurotransmission and brain diseases. Adv Exp Med Biol 2010, 709:95-107.
101. Coelho MH, Silva IJ, Azevedo MS, Manso CF: Decrease in blood histamine in drug-treated parkinsonian patients. Mol Chem Neuropathol 1991, 14(2):77-85.
102. Anichtchik OV, Rinne JO, Kalimo H, Panula P: An altered histaminergic innervation of the substantia nigra in Parkinson's disease. Exp Neurol 2000, 163(1):20-30.
103. Rinne JO, Anichtchik OV, Eriksson KS, Kaslin J, Tuomisto L, Kalimo H, Röyttä M, Panula P: Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy. J Neurochem 2002, 81(5):954-960.
104. Shan L, Bossers K, Luchetti S, Balesar R, Lethbridge N, Chazot PL, Bao AM, Swaab DF: Alterations in the histaminergic system in the substantia nigra and striatum of Parkinson's patients: a postmortem study. Neurobiol Aging 2012, 33(7):1488. e1481-1413.
105. McCarthy M: Autism diagnoses in the US rise by 30%, CDC reports. BMJ 2014, 348:g2520.
106. Linday LA: Oral famotidine: a potential treatment for children with autism. Med Hypotheses 1997, 48(5):381-386.
107. Neville BG, Bentovim A, Clayton BE, Shepherd J: Histidinaemia. Study of relation between clinical and biological findings in 7 subjects. Arch Dis Child 1972, 47(252):190-200.
108. Kotsopoulos S, Kutty KM: Histidinemia and infantile autism. J Autism Dev Disord 1979, 9(1):55-60.
109. Launay JM, Ferrari P, Haimart M, Bursztejn C, Tabuteau F, Braconnier A, Pasques-Bondoux D, Luong C, Dreux C: Serotonin metabolism and other biochemical parameters in infantile autism. A controlled study of 22 autistic children. Neuropsychobiology 1988, 20(1):1-11.
110. Rossi PG, Posar A, Parmeggiani A, Pipitone E, D'Agata M: Niaprazine in the treatment of autistic disorder. J Child Neurol 1999, 14(8):547-550.
111. Rosales-Reynoso MA, Ochoa-Hernández AB, Aguilar-Lemarroy A, Jave-Suárez LF, Troyo-Sanromán R, Barros-Núñez P: Gene expression profiling identifies WNT7A as a possible candidate gene for decreased cancer risk in fragile X syndrome patients. Arch Med Res 2010, 41(2):110-118. e112.
112. Ming X, Stein TP, Barnes V, Rhodes N, Guo L: Metabolic perturbance in autism spectrum disorders: a metabolomics study. J Proteome Res 2012, 11(12):5856-5862.
113. Naushad SM, Jain JM, Prasad CK, Naik U, Akella RR: Autistic children exhibit distinct plasma amino acid profile. Indian J Biochem Biophys 2013, 50(5):474-478.
114. Fernandez TV, Sanders SJ, Yurkiewicz IR, Ercan-Sencicek AG, Kim YS, Fishman DO, Raubeson MJ, Song Y, Yasuno K, Ho WS, Bilguvar K, Glessner J, Chu SH, Leckman JF, King RA, Gilbert DL, Heiman GA, Tischfield JA, Hoekstra PJ, Devlin B, Hakonarson H, Mane SM, Günel M, State MW: Rare copy number variants in tourette syndrome disrupt genes in histaminergic pathways and overlap with autism. Biol Psychiatry 2012, 71(5):392-402.
115. Bambini-Junior V, Baronio D, MacKenzie J, Zanatta G, Dos Santos Riesgo R, Gottfried C: Prenatal exposure to valproate in animals and autism. In Comprehensive Guide to Autism, Volume Volume 3. 1st edition. Edited by Patel VB, Preedy VR, Martin CR. New York: Springer; 2014:1779-1793.